DAX ®12.157,67+0,51%TecDAX ®2.907,62+0,12%Dow Jones26.247,78+0,71%NASDAQ 1007.504,02+0,93%
finanztreff.de

DGAP-Adhoc: Gerresheimer acquires Sensile Medical / irrespective of that, increased growth and improved profitability expected mid-term due to two new major orders with temporarily higher capex / organic revenue guidance 2018 narrowed to upper end of rang

| Quelle: Dow Jones Newswire Web | Lesedauer etwa 4 min. | Text vorlesen Stop Pause Fortsetzen
DGAP-Ad-hoc: Gerresheimer AG / Key word(s): Mergers & Acquisitions
Gerresheimer acquires Sensile Medical / irrespective of that, increased
growth and improved profitability expected mid-term due to two new major
orders with temporarily higher capex / organic revenue guidance 2018
narrowed to upper end of range

11-Jul-2018 / 20:17 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

*Gerresheimer acquires Sensile Medical / irrespective of that, increased
growth and improved profitability expected mid-term due to two new major
orders with temporarily higher capex / organic revenue guidance 2018
narrowed to upper end of range*

Duesseldorf, July 11, 2018 - With the acquisition of Sensile Medical AG,
Switzerland ("Sensile Medical") under a share purchase agreement signed
today, Gerresheimer is extending its business model in the direction of an
Original Equipment Manufacturer (OEM) for drug delivery platforms with
digital and electronic capabilities for pharmaceutical and biopharmaceutical
customers. Sensile Medical develops innovative drug delivery products and
platforms, including digital connected capabilities. It is already working
highly successfully with customers on the development of devices for
diabetics and patients with heart complaints. Depending on the attainment of
contractually specified milestones, the purchase price will be a maximum of
EUR 350m. The initial payment is EUR 175m.

Independently of this, Gerresheimer has secured two new major contracts: one
for the manufacture of inhalers and another for prefillable syringes for a
major heparin producer. At the same time, Gerresheimer has lost a
significantly smaller order in the inhaler business resulting in a
restructuring that will affect the plant in Küssnacht, Switzerland, which is
to be closed by the end of 2019.

As a result and excluding Sensile Medical, there are changes in the planning
of capital expenditures, profitability and revenues: For the years 2019 and
2020, capital expenditures are expected to be higher by two to a maximum of
four percentage points of revenues at constant exchange rates, among other
things for the capacity expansion at the plant in Horsovsky Tyn, Czech
Republic; further automation; and a new plant in Eastern Europe. At the same
time, Gerresheimer anticipates that this will lead in 2019 and 2020 to an
approximately one-percentage-point reduction in the adjusted EBITDA margin
(relative to the financial year 2017) as a consequence of low-margin
revenues in the engineering and tooling business for the new major orders
and of increased expenditures for relocation, employee training and
production start-up/ramp-up.

In the years 2021 and 2022, Gerresheimer expects-again, excluding Sensile
Medical-that both revenues and the adjusted EBITDA margin will increase by
two percentage points beyond the usual rate of growth while capital
expenditures will return to around 8%.
For the current year, following up on the guidance given on February 22,
2018, and excluding Sensile Medical, Gerresheimer anticipates a strong
second half and has narrowed its forecast for revenues at constant exchange
rates to the upper end of the guidance range, at EUR 1.38bn to EUR 1.4bn.

Contact Press Contact Investor Relations
Jens Kürten Severine Camp
Group Senior Director Communication & Marketing Corporate Senior Director
Investor Relations
Phone +49 211 6181-250 Phone +49 211 6181-314
Fax +49 211 6181-241 Fax +49 211 6181-121
E-Mail j.kuerten@gerresheimer.com E-Mail s.camp@gerresheimer.com

Contact:
Severine Camp
Corporate Senior Director Investor Relations
Phone +49 211 6181-314
Fax +49 211 6181-121
E-Mail s.camp@gerresheimer.com

11-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Düsseldorf
Germany
Phone: +49-(0)211/61 81-00
Fax: +49-(0)211/61 81-295
E-mail: s.camp@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6, XS0626028566
WKN: A0LD6E, A1H3VP
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich,
Stuttgart, Tradegate Exchange

End of Announcement DGAP News Service

703763 11-Jul-2018 CET/CEST



(END) Dow Jones Newswires

July 11, 2018 14:17 ET ( 18:17 GMT)
Werbung

Passende Hebelprodukte von

WKN Bezeichnung Hebel
DS5QCG GERRESHEI WaveUnlimited L 70.3143 (DBK) 10,079
DS69HG GERRESHEIMER AG WaveXXL S 80.75 (DBK) 8,326
Werbung

Das könnte Sie auch interessieren

Werbung
Werbung

News-Suche

Suchbegriff:
Werbung
Werbung

Werbung
Börse Stuttgartschliessen
Börse Stuttgart

Gewinnen Sie pures Gold!

Unter allen Teilnehmern an der Anlegerumfrage verlost der Börse Stuttgart Anlegerclub Gold im Gesamtwert von über 1000 Euro.

Jetzt kostenlos anmelden und mitmachen!
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
Glauben Sie, dass - vor dem Hintergrund des möglichen Absturzes in die Bedeutungslosigkeit - die Deutsche Bank und die Commerzbank fusionieren werden?
Jetzt abstimmen!
Alle Umfragen ansehen